Country: Israel
Language: English
Source: Ministry of Health
HYDROCORTISONE; NEOMYCIN AS SULFATE
TEVA ISRAEL LTD
D07CA01
OINTMENT
NEOMYCIN AS SULFATE 0.5 %; HYDROCORTISONE 2.5 %
DERMAL
Required
TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL
HYDROCORTISONE AND ANTIBIOTICS
HYDROCORTISONE AND ANTIBIOTICS
Allergic dermatoses and other corticosteroid responsive inflammatory skin diseases including atopic dermatitis, contact dermatitis, seborrheic dermatitis, anogenital pruritus, infantile eczema and external otitis.
2021-01-31
1 Hycomycin FW Notification 03-2023 PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) - 1986 This medicine is dispensed with a doctor’s prescription only HYCOMYCIN Skin ointment COMPOSITION Hydrocortisone 2.5% Neomycin sulfate 0.5% For information about inactive ingredients and allergens see section 2 under – ‘Important information about some of this medicine’s ingredients’, and section 6 – ‘Additional information’. READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours. 1. WHAT IS THIS MEDICINE INTENDED FOR? Used to treat of inflammatory skin infections. THERAPEUTIC GROUP Hydrocortisone: corticosteroid Neomycin sulfate: an aminoglycoside antibiotic 2. BEFORE USING THIS MEDICINE DO NOT USE THIS MEDICINE IF: • You are sensitive (allergic) to hydrocortisone, neomycin sulfate, other aminoglycoside medicines or to any of the other ingredients that this medicine contains, which are listed in section 6. • You have viral infections, such as cold sores, herpes or chicken pox • You have fungal infections, such as athlete ’ s foot, ringworm, or thrush • You have skin blisters or sores that are caused by a bacterial infection, such as impetigo, tuberculosis of the skin • Like all medicinal products for external use that contain neomycin, do not use this medicine for inflammation of the outer ear if the eardrum is perforated. If any of the above conditions apply to you, consult your doctor or pharmacist. _ _ Special warnings regarding use of this medicine Do not use this medicine on large areas of skin or on open sores unless your doctor tells you to. Do not allow this medicine to come into contact with your eyes. In case of contact, rinse with water immediately Read the complete document
Hycomycin SPC Notification FW 03-2023 Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Hycomycin 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _Active Ingredients _ Hydrocortisone 2.5% Neomycin sulfate 0.5% _ _ For the full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Dermal Ointment. While-yellowish homogenous ointment . 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Allergic dermatoses and other corticosteroid-responsive inflammatory skin diseases including atopic dermatitis, contact dermatitis, seborrheic dermatitis, anogenital pruritus, infantile eczema and external otitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Directions for Use: Apply to the affected area 3-4 times daily. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substances, to other aminoglycoside antibiotics or to any of the excipients listed in section 6.1. Skin lesions, caused by infection with viruses (e.g. herpes simplex, chicken pox), fungi (e.g. candidiasis, tinea) or bacteria (e.g. impetigo). Use is not indicated in treatment of primary or secondary infections due to yeast; or secondary infections due to _Pseudomonas _ or _Proteus _ species. Due to the known ototoxic and nephrotoxic potential of neomycin sulfate, the use of this medicine in large quantities or on large areas for prolonged periods of time is not recommended in circumstances where significant systemic absorption may occur. The ointment should not be applied in the external auditory canal of patients with perforated eardrum. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Hycomycin SPC Notification FW 03-2023 Long term continuous or inappropriate use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are tre Read the complete document